North America In-Vitro Lung Model Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America In-Vitro Lung Model Market size is expected to reach US$ 642.8 Million by 2031 from US$ 186.3 Million in 2024. The market is estimated to record a CAGR of 19.5% from 2025 to 2031.

Executive Summary and North America In-Vitro Lung Model Market Analysis:

The North America in vitro lung model market is divided into the US, Canada, and Mexico. North America is likely to capture a significant share of the global market. Technological innovations have played a pivotal role in enhancing the complexity and functionality of in vitro models. Advancements in tissue engineering, microfluidics, and organ-on-a-chip technologies have enabled the development of more accurate and predictive models for drug discovery and toxicology studies. These innovations facilitate the creation of models that closely mimic human lung physiology, improving the reliability of preclinical testing and reducing the need for animal experiments.

North America, particularly the US, boasts a strong biomedical research infrastructure. The region is home to leading academic institutions, research organizations, and pharmaceutical companies that are at the forefront of in vitro lung modeling research. These institutions have access to state-of-the-art facilities, cutting-edge technologies, and skilled researchers, enabling them to innovate and advance the field. Additionally, the market growth is also fueled by the presence of major industry players, the expansion of animal welfare programs and regulations, and a well-established healthcare infrastructure. Also, favorable government initiatives and a rising number of research collaborations are expected to further boost growth. Supportive healthcare policies, substantial investments in product development, stringent animal welfare laws, and increased awareness campaigns also contribute to the advancement of the market within a mature healthcare environment.

North America In-Vitro Lung Model Market: Strategic Insights

North America In-Vitro Lung Model Market Segmentation Analysis:

• By Type, the North America In-Vitro Lung Model Market is segmented into 3D Models and 2D Models. 3D Model held the largest share of the market in 2024.
• By Application, the North America In-Vitro Lung Model Market is segmented into Drug Discovery and Toxicology Studies, Physiological Research, Regenerative Medicine, and Others. Drug Discovery and Toxicology Studies held the largest share of the market in 2024.
• By End User, the North America In-Vitro Lung Model Market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others. Pharmaceutical and Biotechnology Companies held the largest share of the market in 2024.

North America In-Vitro Lung Model Market Players Density: Understanding Its Impact on Business Dynamics

The North America In-Vitro Lung Model Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America In-Vitro Lung Model Market Outlook

According to a report published by the Global Initiative on Chronic Obstructive Lung Disease, ~65 million people suffer from obstructive pulmonary disease (COPD), and nearly 3 million people die from the disease each year, making it the fourth leading cause of mortality worldwide. Further, the WHO indicates that ~334 million people suffer from asthma. Additionally, COPD was the fourth leading cause of death globally, with 3.5 million deaths reported in 2021. According to the 2023 American Lung Association data, ~34 million Americans were affected by chronic lung diseases such as asthma and COPD. In 2022, ~11.7 million adults, or 4.6% of the population in the US, were diagnosed with COPD. With the growing prevalence of smoking in developing countries and the aging population in high-income countries, the COPD prevalence is projected to rise over the next forty years. As per the World Health Organization (WHO) estimates, COPD will become one of the leading causes of death worldwide by 2030, and it is estimated that by 2060, there will be more than 5.4 million deaths yearly due to COPD and related conditions.

Per the Centers for Disease Control and Prevention (CDC) data, asthma is a common chronic disease globally and affected ~25 million people in the US in 2021. According to the WHO, lung cancer is the most frequently diagnosed cancer and the foremost cause of cancer-related deaths worldwide. in 2022, ~2.5 million individuals were diagnosed with lung cancer, and over 1.8 million people died from the disease. As per the WHO data, from the emergence of COVID-19 in late 2019 to April 2023, the number of reported cases was ~762 million, with 6.81 million associated deaths.

This rising incidence of respiratory diseases is spurring the demand for advanced research models to understand disease mechanisms and develop effective treatments. In vitro lung models provide valuable platforms for studying disease mechanisms and testing potential therapies, thereby supporting the development of effective treatments. Additionally, lung organoids and bioengineered organs-on-chips—both examples of three-dimensional (3D) cell culture models—are valuable tools in respiratory disease research. These models have been successfully used to study how the lung responds to infections by influenza A and coronaviruses, through the lung airways, small airways, and alveoli organ chips.

In vitro lung models, such as precision-cut lung slices (PCLS), allow the study of airway constriction and inflammation, facilitating the evaluation of novel therapeutic targets for asthma and other respiratory conditions. Lung-on-a-chip devices have been developed to replicate the physiological conditions of the human lung. The University of Michigan's "lung-on-a-chip" device uses human lung-tissue cells cultured on a plastic chip with microscopic channels to simulate the conditions inside the lungs, providing new insights into diseases. Thus, the increasing demand for effective treatments and research models fuels the growth of the in vitro lung model market.

North America In-Vitro Lung Model Market Country Insights

By country, the North America In-Vitro Lung Model Market is segmented into the United States, Canada and Mexico. The United States held the largest share in 2024.

The Asthma and Allergy Foundation of America 2023 states that ~26 million people in the US had asthma in 2022 (i.e., ~1 in 13 people in the country). Moreover, ~3,517 death cases were recorded due to asthma in 2021. Similarly, lung cancer is the third most common cancer, and more people die from lung cancer than other type of cancer in the country. As per the US Cancer Statistics Lung Cancer Stat Bite, in 2021, ~209,500 new lung cancers were reported, and ~131,888 people died from lung cancer in 2022. The rising incidence of lung-related diseases necessitates the development of effective treatments, driving the adoption of innovative research models to understand the disease pathogenesis.
Several organizations are collaborating on research activities. For instance, ATCC is collaborating with the Human Cancer Models Initiative to offer an extensive variety of next-generation 2D and 3D patient-derived in vitro cancer models, including organoids. Additionally, in October 2023, a multidisciplinary research team from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston Children's Hospital-led by the Wyss Founding Director and supported by FDA funding-developed a human in vitro model that closely replicates the complexity of radiation-induced lung injury (RILI) and the radiation sensitivity of the human lung. Using a previously developed microfluidic human Lung Alveolus Chip-lined with human lung alveolar epithelial cells and interfaced with lung capillary endothelial cells to mimic the alveolar-capillary interface-the team successfully recreated key features of RILI. These included radiation-induced DNA damage, cell-type-specific gene expression changes, inflammation, and injury to both epithelial and endothelial cells. Additionally, by testing the potential of two drugs to suppress the effects of acute RILI, the researchers demonstrated the model's potential as a highly human-relevant preclinical platform for drug discovery. This advanced, life-like human in vitro model offers a unique opportunity to study early disease mechanisms and accelerate the development of treatments for radiation-induced lung damage. These contribute to the development of more effective treatments and a deeper understanding of lung diseases.

North America In-Vitro Lung Model Market Company Profiles

Some of the key players operating in the market include Charles River Laboratories International Inc, Lonza Group AG, Merck KGaA, American Type Culture Collection (ATCC), Draper, Inc., PromoCell GmbH, Emulate, Inc., MIMETAS BV, Organovo Holdings Inc, MatTek Corp, CN Bio Innovations Ltd, InSphero AG, Epithelix, AlveoliX AG and TissUse GmbH

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America In-Vitro Lung Model Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise